Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2018-99-116577

Published: 2018

Journal Articles

Immune Tolerance Induction with Simoctocog Alfa (Nuwiq ® ) in Six Patients with Severe Haemophilia a and FVIII Inhibitors

Neha Bhatnagar, ND, Kate Khair, Ri Liesner, Alice Wilkinson, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2018-99-118041

Published: 2018

Journal Articles

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Ri Liesner, Joris Versteden, Shannely Lowndes, Larisa Belyanskaya, PhD, Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD

Blood (2018) 132 (Supplement 1): 1204.

https://doi.org/10.1182/blood-2018-99-110608

Published: 2018

Journal Articles

Comparison of the Functional Characteristics and Post-Translational Modifications of Commercial Factor VIII Products

Guido Kohla, PhD, Larisa Belyanskaya, PhD, Maya Tiemeyer, PhD, Thole Züchner, PhD, Irena Knappik, PhD, Julia Rosenlöcher, PhD

Blood (2017) 130 (Supplement 1): 2362.

https://doi.org/10.1182/blood.V130.Suppl_1.2362.2362

Published: 2017

Journal Articles

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Sri Adapa, BSPharm, MBA, Olga Ovcinnikova, MSc, Ian Leighton, PhD, Shamika de Silva, PhD, Matthew Bending, PhD, Larisa Belyanskaya, PhD, Cosentino Lidia, PhD, Anne Myerson, MSc

Blood (2017) 130 (Supplement 1): 4929.

https://doi.org/10.1182/blood.V130.Suppl_1.4929.4929

Published: 2017

NARROW

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Immune Tolerance Induction with Simoctocog Alfa (Nuwiq ® ) in Six Patients with Severe Haemophilia a and FVIII Inhibitors

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Comparison of the Functional Characteristics and Post-Translational Modifications of Commercial Factor VIII Products

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Email alerts

ASH Publications

American Society of Hematology

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Immune Tolerance Induction with Simoctocog Alfa (Nuwiq ® ) in Six Patients with Severe Haemophilia a and FVIII Inhibitors

Immunogenicity of Two Plasma-Derived FVIII Products and Simoctocog Alfa in Previously Untreated Patients According to F8 Mutation Type

Comparison of the Functional Characteristics and Post-Translational Modifications of Commercial Factor VIII Products

Budget Impact Analysis of a New-Generation Recombinant Factor VIII from a Human Cell Line (Nuwiq) for the Treatment of Patients with Hemophilia A in Canada

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only